Effects of different dosages of vitamin D3 on anthropometric indices, metabolic, bone, and vascular parameters and body composition

Effects of different dosages of vitamin D3 on anthropometric indices, metabolic, bone, and vascular parameters and body composition in overweight or obese children and adolescents

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180805040703N1

Enrollment

327

Registered

2018-10-20

Start date

2016-06-20

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: over weight and obesity, cardiovascular disease. Condition 2: vitamin D deficiency. Overweight and obesity Vitamin D deficiency

Interventions

Intervention 1: Intervention group1: 12 months oral vitamin D supplementation of 2000 IU/d (ZAHRAVI pharmaceutical company-Tabriz-Iran). Intervention 2: Intervention group2: 12 months oral vitamin D s

Eligibility

Sex/Gender

All

Age

6 Years to 13 Years

Inclusion criteria

Inclusion criteria: Willingness to cooperate Age 6-13 years Overweight or obesity (BMI = 85th percentile national scale by age and sex)

Exclusion criteria

Exclusion criteria: Reluctance to cooperate in any stage of study Use of any vitamin D supplements during the last six months Identifying any types of liver diseases, kidney, cardiovascular and metabolic bone Use of any drugs, affecting metabolism of vitamin D including glucocorticoids, steroids and anticonvulsants such as carbamazepine, phenytoin and phenobarbital Following any weight loss diets during the past one year

Design outcomes

Primary

Measure	Time frame
Carotid intima media thickness. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: sonography.	—

Secondary

Measure	Time frame
25 hydroxy vitamin D. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Electrochemiluminescence.;Para thyroid hormon. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Electrochemiluminescence.;Plasma insulin. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Electrochemiluminescence.;Plasma glucose. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.;Lipid profile. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.;Body mass index. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: calculation.;Fat mass. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: bioimpedance analysis.;Lean mass. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: bioimpedance analysis.;Systolic and diastolic blood pressure. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Sphygmomanometer.;Calcium. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.;Phosphorus. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.	—

Measure

Time frame

25 hydroxy vitamin D. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Electrochemiluminescence.;Para thyroid hormon. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Electrochemiluminescence.;Plasma insulin. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Electrochemiluminescence.;Plasma glucose. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.;Lipid profile. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.;Body mass index. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: calculation.;Fat mass. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: bioimpedance analysis.;Lean mass. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: bioimpedance analysis.;Systolic and diastolic blood pressure. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: Sphygmomanometer.;Calcium. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.;Phosphorus. Timepoint: before intervention, 6 and 12 months after intervention. Method of measurement: colorimetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolaleh Asghari

Institute for Endocrine Science

g_asghari@hotmail.com+98 21 2243 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026